You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Dow
AstraZeneca
Baxter
Moodys
Boehringer Ingelheim

Last Updated: November 30, 2020

DrugPatentWatch Database Preview

TICLID Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Ticlid patents expire, and what generic alternatives are available?

Ticlid is a drug marketed by Roche Palo and is included in one NDA.

The generic ingredient in TICLID is ticlopidine hydrochloride. There are nine drug master file entries for this compound. Additional details are available on the ticlopidine hydrochloride profile page.

Summary for TICLID
Drug patent expirations by year for TICLID
Recent Clinical Trials for TICLID

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dammam UniversityPhase 4
Dammam Central HospitalPhase 4
King Fahad Armed Forces HospitalPhase 4

See all TICLID clinical trials

US Patents and Regulatory Information for TICLID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Roche Palo TICLID ticlopidine hydrochloride TABLET;ORAL 019979-001 Mar 24, 1993 DISCN No No   Start Trial   Start Trial   Start Trial
Roche Palo TICLID ticlopidine hydrochloride TABLET;ORAL 019979-002 Oct 31, 1991 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TICLID

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Roche Palo TICLID ticlopidine hydrochloride TABLET;ORAL 019979-001 Mar 24, 1993   Start Trial   Start Trial
Roche Palo TICLID ticlopidine hydrochloride TABLET;ORAL 019979-002 Oct 31, 1991   Start Trial   Start Trial
Roche Palo TICLID ticlopidine hydrochloride TABLET;ORAL 019979-002 Oct 31, 1991   Start Trial   Start Trial
Roche Palo TICLID ticlopidine hydrochloride TABLET;ORAL 019979-001 Mar 24, 1993   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
McKinsey
Baxter
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.